Testosterone Therapy May Help Prevent Fractures

A study has shown that testosterone therapy can decrease the risk of osteoporosis in hypogonadal men by significantly increasing bone mineral density, which can prevent future bone loss and may help prevent the associated risk of fractures. The findings were presented at the annual meeting of the American Society for Bone and Mineral Research in Minneapolis (MN, USA).

The study involved 291 hypogonadal males with a mean age of 58 years, who were followed for 12 months to determine the effects of testosterone replacement therapy on bone mineral density. By month 12, serum testosterone levels were in the normal range and the average mineral density of the lumbar spine rose 2.75%. In addition, body composition also improved, with a 2.42% increase in lean body mass and a 2.35% decrease in fat mass. About 20% of men over 50 experience hypogonadism. In the study, the researchers used Testim testosterone gel, produced by Auxilium Pharmaceuticals (Norristown, PA, USA).

"The study results show that Testim gel can produce significant increases in bone mineral density and improvement in body composition, helping to prevent future bone loss and also decreasing the risk of bone fractures in aging males,” said Romeo Bachand, M.D., Ph.D., chief scientific officer of Auxilium.




Related Links:
Auxilium